学术探索
学术期刊
新闻热点
数据分析
智能评审

Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004

被引：55
作者：
Furst, DE
Breedveld, FC
Kalden, JR
Smolen, JS
Burmester, GR
Bijlsma, JWJ
Dougados, M
Emery, P
Keystone, EC
Klareskog, L
Mease, PJ
机构：
[1] Univ Calif Los Angeles, Div Rheumatol, Los Angeles, CA USA
[2] Leiden Univ, Med Ctr, Dept Rheumatol, Leiden, Netherlands
[3] Univ Erlangen Nurnberg, Inst Clin Immunol, Dept Internal Med 3, Erlangen, Germany
[4] Vienna Gen Hosp, Clin Internal Med 3, Inst Rheumatol, Vienna, Austria
[5] Charite Hosp, Dept Rheumatol & Clin Immunol, Berlin, Germany
[6] Univ Utrecht, Med Ctr, Dept Rheumatol & Clin Immunol, Utrecht, Netherlands
[7] Hop Cochin, Inst Rhumatol, Paris, France
[8] Univ Leeds, Gen Infirm, Dept Rheumatol, Leeds LS1 3EX, W Yorkshire, England
[9] Mt Sinai Hosp, Dept Rheumatol, Toronto, ON, Canada
[10] Karolinska Hosp, Dept Med, Rheumatol Unit, S-10401 Stockholm, Sweden
[11] Swedish Med Ctr, Med Ctr, Seattle, WA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2004年 / 63卷
关键词：
D O I：
10.1136/ard.2004.029272
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2 / 12
页数：11
相关论文
共 169 条
  • [1] Experience with infliximab (anti-TNFα monoclonal antibody) as monotherapy for giant cell arteritis
    Andonopoulos, AP
    Meimaris, N
    Daoussis, D
    Bounas, A
    Giannopoulos, G
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (11) : 1116 - 1116
  • [2] How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH
    Anker, SD
    Coats, AJS
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2002, 86 (2-3) : 123 - 130
  • [3] Open-label study of infliximab treatment for psoriatic arthritis: Clinical and magnetic resonance imaging measurements of reduction of inflammation
    Antoni, C
    Dechant, C
    Lorenz, PDHM
    Wendler, J
    Ogilvie, A
    Lueftl, M
    Kalden-Nemeth, D
    Kalden, JR
    Manger, B
    [J]. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2002, 47 (05): : 506 - 512
  • [4] Antoni CE, 2001, ARTHRITIS RHEUM, V44, pS152
  • [5] Athreya BH, 2000, ARTHRITIS RHEUM, V43, pS117
  • [6] Disease activity and risk of lymphoma in patients with rheumatoid arthritis:: nested case-control study
    Baecklund, E
    Ekbom, A
    Sparén, P
    Feltelius, N
    Klareskog, L
    [J]. BRITISH MEDICAL JOURNAL, 1998, 317 (7152) : 180 - 181
  • [7] Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
    Baert, F
    Noman, M
    Vermeire, S
    Van Assche, G
    D'Haens, G
    Carbonez, A
    Rutgeerts, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) : 601 - 608
  • [8] Baeten D, 2000, ARTHRITIS RHEUM, V43, pS404
  • [9] Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?
    Baeten, D
    Kruithof, E
    Van den Bosch, F
    Van den Bossche, N
    Herssens, A
    Mielants, H
    De Keyser, F
    Veys, EM
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (09) : 829 - 834
  • [10] Baeten D, 2002, ARTHRITIS RHEUM-US, V46, pS432
12345678910